Business Wire

Selig Group Announces Acquisition of Performance Systematix

5.1.2021 16:30:00 EET | Business Wire | Press release

Share

Selig Group (“Selig”), owned by CC Industries (“CCI”), announced today that it has completed an acquisition of Performance Systematix (“PSI”). Founded in 1984, PSI is the leading supplier of container and packaging venting solutions worldwide, which protect container integrity, eliminate waste, and reduce shipping costs. The combination provides Selig with highly complementary adjacent capabilities to serve its customers more broadly on a global basis. This transaction is Selig’s third acquisition and reflects its strategy to augment growth and expand its business model via complementary solutions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210105005048/en/

“PSI is an exceptional company with a long history of growth, and has built its success on solving customers’ problems, a core value that Selig shares,” said Bill Crown, President and Chief Executive Officer of CCI. “We look forward to supporting both Selig and PSI’s continued growth globally and further expanding the combined company’s capabilities and solutions.”

Steve Cassidy, President and Chief Executive Officer of Selig added, “PSI’s culture of innovation, service and quality are well-aligned with Selig and will enable us to serve customers better as a combined organization with expanded capabilities and short, highly responsive product development cycles.”

Glenn Dunn, PSI’s President stated, “Selig is an ideal partner to support PSI’s team in its next phase of growth. This is a highly strategic combination which expands both companies’ product lines, enabling us to provide a more comprehensive solutions offering for customers globally. We will continue to focus on the innovative, high quality products and the exemplary service our customers rely upon.”

PSI will operate as a subsidiary of Selig and continue serving its customers from its Grand Rapids, Michigan, USA facility.

About Selig Group (www.seligsealing.com)

Selig Group is a leading global flexible packaging company. The company is the leading global supplier of innovative, technically-differentiated closure lining solutions for food, beverage, pharmaceutical, healthcare, personal care and industrial applications. Selig also manufacturers a range of technical and flexible packaging products in Europe for pouch and other applications. The company’s products are designed to serve customers’ needs for ensuring freshness, extending shelf life, providing tamper evidence, counterfeit deterrence, e-commerce and brand protection. Selig is headquartered in Naperville, Illinois with manufacturing and distribution locations worldwide.

About Performance Systematix (www.psix.com)

PSI is the leading supplier of engineered and vented packaging solutions worldwide. Customers rely on the company’s engineered solutions for applications where packaged products experience off-gassing, pressure changes, temperature changes, or handling variability. Over its history, PSI has grown by developing new solutions and providing reliable and consistent quality and service to customers. The company serves a global customer base from its facility in Grand Rapids, Michigan, USA.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

SELIG GROUP CONTACT
John Brown
jbrown@seligsealing.com
+1 630 615 7240

PERFORMANCE SYSTEMATIX CONTACT
John Grover
jgrover@psix.com
+1 616 949 9090

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye